Naiyer Shahzad

Mr. Naiyer Shahzad


Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2018 in Biomedicine & Pharmacotherapy
Verified
Journal Article
Closed access
SGSivapragasam Gothai
Sivapragasam Gothai
KMKatyakyini Muniandy
Katyakyini Muniandy
CGCharles Gnanaraj
Charles Gnanaraj
IIIbrahim Abdel Aziz Ibrahim
Ibrahim Abdel Aziz Ibrahim
NSNaiyer Shahzad
Naiyer Shahzad
APArulselvan Palanisamy
Arulselvan Palanisamy

1 February 2014 in Pharmacology Biochemistry and Behavior
Verified
Journal Article
Closed access
NSNaiyer Shahzad
Naiyer Shahzad
Javed AhmadJaved Ahmad
Javed Ahmad
WKWajahatullah Khan
Wajahatullah Khan
SASaeed S. Al-Ghamdi
Saeed S. Al-Ghamdi
MAM. Ruhal Ain
M. Ruhal Ain
DKDr. RAZIA KHANAM
Dr. RAZIA KHANAM

30 November 2021 in Gels
Verified
Journal Article
Open access
PDF file
Shadab MDShadab MD
Shadab MD
SASamaa T. Abdullah
Samaa T. Abdullah
NANabil A. Alhakamy
Nabil A. Alhakamy
ABAhmad Bani-Jaber
Ahmad Bani-Jaber
ARAmmu Kutty Radhakrishnan
Ammu Kutty Radhakrishnan
WRWaleed Y. Rizg
Waleed Y. Rizg
This study aimed to develop gastro-retentive sustained-release ambroxol (ABX) nanosuspensions utilizing ambroxol-kappa-carrageenan (ABX-CRGK) complexation formulations. The complex was characterized by differential scanning calorimetry, powder x-ray diffractometer, and scanning electron microscopy. The prepared co-precipitate complex was used for the development of the sustained-release formulation to overcome the high metabolic and poor solubility problems associated with ABX. Furthermore, the co-precipitate complex was formulated as a suspension in an aqueous floating gel-forming vehicle of sodium alginate with chitosan, which might be beneficial for targeting the stomach as a good absorption site for ABX. The suspension exhibited rapid floating gel behaviour for more than 8 h, thus confirming the gastro-retentive effects. Particle size analysis revealed that the optimum nanosuspension (ABX-NS) had a mean particle size of 332.3 nm. Afterward, the ABX released by the nanoparticles would be distributed to the pulmonary tissue as previously described. Based on extensive pulmonary distribution, the developed nanosuspension-released ABX nanoparticles showed significant cytotoxic enhancement compared to free ABX in A549 lung cancer cells. However, a significant loss of mitochondrial membrane potential (MMP) also occurred. The level of caspase-3 was the highest in the ABX-NS-released particle-treated samples, with a value of 416.6 ± 9.11 pg/mL. Meanwhile, the levels of nuclear factor kappa beta, interleukins 6 and 1 beta, and tumour necrosis alpha (NF-kB, IL-6, IL-1β, and TNF-α, respectively) were lower for ABX-NS compared to free ABX (p < 0.05). In caspase-3, Bax, and p53, levels significantly increased in the presence of ABX-NS compared to free ABX. Overall, ABX-NS produced an enhancement of the anticancer effects of ABX on the A549 cells, and the developed sustained-release gel was successful in providing a gastro-retentive effect.

22 October 2015 in African Journal of Pharmacy and Pharmacology
Verified
Journal Article
Open access
PDF file
AMA Afify Mohamed
A Afify Mohamed
NSNaiyer Shahzad
Naiyer Shahzad
TNTawfik Nazik
Tawfik Nazik
AIA Ibrahim Ibrahim
A Ibrahim Ibrahim
AZAbduljaleel Zainularifeen
Abduljaleel Zainularifeen
SSS Al Ghamdi Saeed
S Al Ghamdi Saeed
The study of prescribing pattern is a significant constituent of medical review, which helps in monitoring, evaluating and building required modifications in the prescribing practices to attain a rational and cost effective medical care. The present study determined the trends in drug prescription pattern of clinicians in private and general hospitals in Makkah, Saudi Arabia. One thousand two hundred and thirty two prescriptions were collected from private and general hospitals between March and September, 2013. The prescriptions were subjected to analysis using the World Health Organization (WHO) drug use indicators. The study cleared that all collected prescriptions were titled with the name of hospital and some were handwritten and the others were computer printouts. Readability was evident in 58.3% of handwritten prescriptions. The name, address, date, license number, and signature of the prescriber was presented in 71.8, 95.1, 71.8, 47.4 and 77.9% of all prescriptions, respectively. Name of patient, age, sex and address were presented in 81.5, 64.0, 61.0 and 20.5% in all prescriptions, respectively. The diagnosis of complaint or a history of allergy was presented in 44.5 and 12.7%, respectively of all prescriptions. The prescribed drugs in a generic name were 32.8% of all prescriptions. The strength, the drug dosage form, the route and frequency of administration of the prescribed drug were presented in 84.1, 58.1, 33.8 and 93.2% of all prescriptions, respectively whereas, duration of treatment was mentioned in only 12.0% of total prescriptions. The average number of drugs per encounter was 2.8. Prescribers were prescribed one, two, three, four, five or more than five drugs per prescription in 1.7, 41.1, 35.3, 16.2, 3.7 and 2.3%, respectively. This study revealed that it is necessary to further improve drugs prescribing practice. This calls for sustained interventional strategies and periodic review at all levels of healthcare for the avoidance of negative consequences of inappropriate prescription. Polypharmacy and low rate of generic prescriptions remain problems in healthcare facilities. Key words: Prescribing practice, drug use indicator, hospitals, prescriptions.